DelRicht Research
DelRicht Research
Prosper, Texas, United States4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT07287644 | |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 4 | 2026-09-28 | NCT07266558 | |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | Acneiform Eruptions, Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, acne, bacterial infectious disease, dermatitis, hidradenitis, hidradenitis suppurativa, sebaceous gland disorder, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 2 | 2026-06-30 | NCT06993610 | |
| A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine | DNA Virus Infections, Disease Attributes, Herpesviridae infectious disease, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Varicella Zoster Virus Infection, herpes zoster, infectious disease, viral infectious disease | Active, not recruiting | Phase 2 | 2026-04-23 | NCT06581575 |